Oral gene delivery with cyclo -(d -Trp-Tyr) peptide nanotubes

Wei Hsien Hsieh, Shwu Fen Chang, Hui Min Chen, Jeng Hsien Chen, Jiahorng Liaw

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The feasibility of cyclo-(d-Trp-Tyr) peptide nanotubes (PNTs) as oral gene delivery carriers was investigated in nude mice with eight 40 μg doses of pCMV-lacZ in 2 days at 3 h intervals. The association between DNA and PNTs, the DNase I stability of PNTs-associated DNA, and in vitro permeability of DNA were estimated. The results showed that the cyclo-(d-Trp-Tyr) PNTs self-associated at concentrations above 0.01 mg/mL. Plasmid DNA associated with PNTs with a binding constant of 3.2 × 108 M-1 calculated by a fluorescence quenching assay. PNTs were able to protect DNA from DNase I, acid, and bile digestion for 50 min, 60 min, and 180 min, respectively. The in vitro duodenal apparent permeability coefficient of pCMV-lacZ calculated from a steady state flux was increased from 49.2 ± 21.6 × 10-10 cm/s of naked DNA to 395.6 ± 142.2 × 10-10 cm/s of pCMV-lacZ/PNT formulation. The permeation of pCMV-lacZ formulated with PNTs was found in an energy-dependent process. Furthermore, β-galatosidase (β-Gal) activity in tissues was quantitatively assessed using chlorophenol red-β-d-galactopyranoside (CPRG) and was significantly increased by 41% in the kidneys at 48 h and by 49, 63, and 46% in the stomach, duodenum, and liver, respectively, at 72 h after the first dose of oral delivery of pCMV-lacZ/PNT formulation. The organs with β-Gal activity were confirmed for the presence of pCMV-lacZ DNA with Southern blotting analysis and intracellular tracing the TM-rhodamine-labeled DNA and the presence of mRNA by reverse transcription-real time quantitative PCR (RT-qPCR). Another plasmid (pCMV-hRluc) encoding Renilla reniformis luciferase was used to confirm the results. An increased hRluc mRNA and luciferase in stomach, duodenum, liver, and kidney were detected by RT-qPCR, ex vivo bioluminescence imaging, luciferase activity quantification, and immunostaining, respectively.

Original languageEnglish
Pages (from-to)1231-1249
Number of pages19
JournalMolecular Pharmaceutics
Volume9
Issue number5
DOIs
Publication statusPublished - May 7 2012

Fingerprint

tryptophyltyrosine
Peptide Nanotubes
DNA
Genes
Deoxyribonuclease I
Luciferases
Duodenum
Real-Time Polymerase Chain Reaction
Permeability
Stomach
Plasmids
Renilla Luciferases
Kidney
Messenger RNA
Rhodamines
Liver
Southern Blotting
Bile Acids and Salts
Nude Mice

Keywords

  • gene delivery
  • oral
  • peptide nanotubes

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Medicine
  • Drug Discovery

Cite this

Oral gene delivery with cyclo -(d -Trp-Tyr) peptide nanotubes. / Hsieh, Wei Hsien; Chang, Shwu Fen; Chen, Hui Min; Chen, Jeng Hsien; Liaw, Jiahorng.

In: Molecular Pharmaceutics, Vol. 9, No. 5, 07.05.2012, p. 1231-1249.

Research output: Contribution to journalArticle

Hsieh, Wei Hsien ; Chang, Shwu Fen ; Chen, Hui Min ; Chen, Jeng Hsien ; Liaw, Jiahorng. / Oral gene delivery with cyclo -(d -Trp-Tyr) peptide nanotubes. In: Molecular Pharmaceutics. 2012 ; Vol. 9, No. 5. pp. 1231-1249.
@article{2503021e5bca4994a91ce3c91d9bf139,
title = "Oral gene delivery with cyclo -(d -Trp-Tyr) peptide nanotubes",
abstract = "The feasibility of cyclo-(d-Trp-Tyr) peptide nanotubes (PNTs) as oral gene delivery carriers was investigated in nude mice with eight 40 μg doses of pCMV-lacZ in 2 days at 3 h intervals. The association between DNA and PNTs, the DNase I stability of PNTs-associated DNA, and in vitro permeability of DNA were estimated. The results showed that the cyclo-(d-Trp-Tyr) PNTs self-associated at concentrations above 0.01 mg/mL. Plasmid DNA associated with PNTs with a binding constant of 3.2 × 108 M-1 calculated by a fluorescence quenching assay. PNTs were able to protect DNA from DNase I, acid, and bile digestion for 50 min, 60 min, and 180 min, respectively. The in vitro duodenal apparent permeability coefficient of pCMV-lacZ calculated from a steady state flux was increased from 49.2 ± 21.6 × 10-10 cm/s of naked DNA to 395.6 ± 142.2 × 10-10 cm/s of pCMV-lacZ/PNT formulation. The permeation of pCMV-lacZ formulated with PNTs was found in an energy-dependent process. Furthermore, β-galatosidase (β-Gal) activity in tissues was quantitatively assessed using chlorophenol red-β-d-galactopyranoside (CPRG) and was significantly increased by 41{\%} in the kidneys at 48 h and by 49, 63, and 46{\%} in the stomach, duodenum, and liver, respectively, at 72 h after the first dose of oral delivery of pCMV-lacZ/PNT formulation. The organs with β-Gal activity were confirmed for the presence of pCMV-lacZ DNA with Southern blotting analysis and intracellular tracing the TM-rhodamine-labeled DNA and the presence of mRNA by reverse transcription-real time quantitative PCR (RT-qPCR). Another plasmid (pCMV-hRluc) encoding Renilla reniformis luciferase was used to confirm the results. An increased hRluc mRNA and luciferase in stomach, duodenum, liver, and kidney were detected by RT-qPCR, ex vivo bioluminescence imaging, luciferase activity quantification, and immunostaining, respectively.",
keywords = "gene delivery, oral, peptide nanotubes",
author = "Hsieh, {Wei Hsien} and Chang, {Shwu Fen} and Chen, {Hui Min} and Chen, {Jeng Hsien} and Jiahorng Liaw",
year = "2012",
month = "5",
day = "7",
doi = "10.1021/mp200523n",
language = "English",
volume = "9",
pages = "1231--1249",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Oral gene delivery with cyclo -(d -Trp-Tyr) peptide nanotubes

AU - Hsieh, Wei Hsien

AU - Chang, Shwu Fen

AU - Chen, Hui Min

AU - Chen, Jeng Hsien

AU - Liaw, Jiahorng

PY - 2012/5/7

Y1 - 2012/5/7

N2 - The feasibility of cyclo-(d-Trp-Tyr) peptide nanotubes (PNTs) as oral gene delivery carriers was investigated in nude mice with eight 40 μg doses of pCMV-lacZ in 2 days at 3 h intervals. The association between DNA and PNTs, the DNase I stability of PNTs-associated DNA, and in vitro permeability of DNA were estimated. The results showed that the cyclo-(d-Trp-Tyr) PNTs self-associated at concentrations above 0.01 mg/mL. Plasmid DNA associated with PNTs with a binding constant of 3.2 × 108 M-1 calculated by a fluorescence quenching assay. PNTs were able to protect DNA from DNase I, acid, and bile digestion for 50 min, 60 min, and 180 min, respectively. The in vitro duodenal apparent permeability coefficient of pCMV-lacZ calculated from a steady state flux was increased from 49.2 ± 21.6 × 10-10 cm/s of naked DNA to 395.6 ± 142.2 × 10-10 cm/s of pCMV-lacZ/PNT formulation. The permeation of pCMV-lacZ formulated with PNTs was found in an energy-dependent process. Furthermore, β-galatosidase (β-Gal) activity in tissues was quantitatively assessed using chlorophenol red-β-d-galactopyranoside (CPRG) and was significantly increased by 41% in the kidneys at 48 h and by 49, 63, and 46% in the stomach, duodenum, and liver, respectively, at 72 h after the first dose of oral delivery of pCMV-lacZ/PNT formulation. The organs with β-Gal activity were confirmed for the presence of pCMV-lacZ DNA with Southern blotting analysis and intracellular tracing the TM-rhodamine-labeled DNA and the presence of mRNA by reverse transcription-real time quantitative PCR (RT-qPCR). Another plasmid (pCMV-hRluc) encoding Renilla reniformis luciferase was used to confirm the results. An increased hRluc mRNA and luciferase in stomach, duodenum, liver, and kidney were detected by RT-qPCR, ex vivo bioluminescence imaging, luciferase activity quantification, and immunostaining, respectively.

AB - The feasibility of cyclo-(d-Trp-Tyr) peptide nanotubes (PNTs) as oral gene delivery carriers was investigated in nude mice with eight 40 μg doses of pCMV-lacZ in 2 days at 3 h intervals. The association between DNA and PNTs, the DNase I stability of PNTs-associated DNA, and in vitro permeability of DNA were estimated. The results showed that the cyclo-(d-Trp-Tyr) PNTs self-associated at concentrations above 0.01 mg/mL. Plasmid DNA associated with PNTs with a binding constant of 3.2 × 108 M-1 calculated by a fluorescence quenching assay. PNTs were able to protect DNA from DNase I, acid, and bile digestion for 50 min, 60 min, and 180 min, respectively. The in vitro duodenal apparent permeability coefficient of pCMV-lacZ calculated from a steady state flux was increased from 49.2 ± 21.6 × 10-10 cm/s of naked DNA to 395.6 ± 142.2 × 10-10 cm/s of pCMV-lacZ/PNT formulation. The permeation of pCMV-lacZ formulated with PNTs was found in an energy-dependent process. Furthermore, β-galatosidase (β-Gal) activity in tissues was quantitatively assessed using chlorophenol red-β-d-galactopyranoside (CPRG) and was significantly increased by 41% in the kidneys at 48 h and by 49, 63, and 46% in the stomach, duodenum, and liver, respectively, at 72 h after the first dose of oral delivery of pCMV-lacZ/PNT formulation. The organs with β-Gal activity were confirmed for the presence of pCMV-lacZ DNA with Southern blotting analysis and intracellular tracing the TM-rhodamine-labeled DNA and the presence of mRNA by reverse transcription-real time quantitative PCR (RT-qPCR). Another plasmid (pCMV-hRluc) encoding Renilla reniformis luciferase was used to confirm the results. An increased hRluc mRNA and luciferase in stomach, duodenum, liver, and kidney were detected by RT-qPCR, ex vivo bioluminescence imaging, luciferase activity quantification, and immunostaining, respectively.

KW - gene delivery

KW - oral

KW - peptide nanotubes

UR - http://www.scopus.com/inward/record.url?scp=84860765484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860765484&partnerID=8YFLogxK

U2 - 10.1021/mp200523n

DO - 10.1021/mp200523n

M3 - Article

C2 - 22480317

AN - SCOPUS:84860765484

VL - 9

SP - 1231

EP - 1249

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 5

ER -